Initial data from the Esprit BTK post-approval study, presented at the 2026 Charing Cross (CX) Symposium (21–23 April, London, UK), revealed “promising” 30-day results, according to an Abbott press release. The data showed the company’s Esprit BTK everolimus-eluting resorbable scaffold system is a safe and effective approach in patients with very challenging chronic limb-threatening ischaemia […] The post Abbott unveils “promising” Esprit BTK post-approval study data appeared first on Cardiovascular News .